Jordan Dubow, M.D., is a board-certified neurologist with fellowship training in movement disorders and vascular neurology. Prior to joining Paragon, he was the chief medical officer at Avadel Pharmaceuticals. Dr. Dubow also was vice president of CNS Therapeutic Strategy at Esteve Pharmaceuticals. Earlier, he was the vice president of clinical and medical affairs at Clintrex, LLC, a strategic advisory firm. Dr. Dubow served as the chief medical officer for Marathon Pharmaceuticals and the vice president of clinical development and medical affairs at Cynapsus Therapeutics. He has played a pivotal role on nine new drug applications (NDAs) in the U.S. as well as numerous NDAs in Europe, Japan, Canada, and Australia. Dr. Dubow began his career as an academic neurologist focusing on Parkinson’s disease and stroke. He completed medical school and a neurology residency at the Northwestern University Feinberg School of Medicine, a movement disorders fellowship at a Northwestern University-affiliated hospital and a vascular neurology fellowship at New York Presbyterian/Weil Cornell Medical Center.